The abstract is read at the publisher; the summary is JClub's.
Genetic Fas deletion in an autochthonous Rb1/Trp53-deficient small-cell lung cancer mouse model markedly suppresses liver metastatic disease, though it does not improve survival.
- Why it matters: Durable control in small-cell lung cancer remains difficult despite immunotherapy, and Fas-Fas ligand signalling is an underexplored vulnerability linked to metastatic progression.
- What they did: In established disease, six administrations over three weeks of a soluble Fas-Fc fusion protein were tested, with liver metastasis burden and survival measured alongside transcriptional and immune readouts.
- The result: FasL blockade significantly prolonged survival and substantially reduced liver metastasis incidence and burden, with liver inflammatory/immune-response signatures increasing; adding anti-PD-1 increased pulmonary immune-cell accumulation without extra survival benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.